Carel B. Hoyng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carel B. Hoyng has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Frans P. M. Cremers
4 shared publications- Frans P. M. Cremers
Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
4 shared publications Sioe Lie Go
Department of Ophthalmology, University Medical Centre Nijmegen, 6500 HB Nijmegen, the Netherlands
3 shared publications- Thomas Theelen
Department of Ophthalmology, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, The Netherlands
3 shared publications - Arijit Mukhopadhyay
Translational Medicine Laboratory, Biomedical Research and Innovation Centre, University of Salford, Manchester M5 4WT, UK
2 shared publications August F. Deutman
Department of Ophthalmology, University Medical Centre Nijmegen, Nijmegen, The Netherlands
2 shared publications
Latest Publications
- Open Access
- 27 June 2016
- Published by Wiley in Acta Ophthalmologica
- Vol. 95 (5) , e426-e427
Switching to aflibercept in patients with neovascular age-related macular degeneration not responding to bevacizumab: a pilot study
- 27 June 2016
- Published by Wiley in Acta Ophthalmologica
- Vol. 95 (5) , e426-e427
Open AccessSwitching to aflibercept in patients with neovascular age-related macular degeneration not responding to bevacizumab: a pilot study
- Open Access
- 7 July 2015
- Published by Springer Nature in BMC Ophthalmology
- Vol. 15 (1) , 71
Comparing the effectiveness and costs of Bevacizumab to Ranibizumab in patients with Diabetic Macular Edema: a randomized clinical trial (the BRDME study)
The effectiveness of ranibizumab in the treatment of diabetic macular edema has been proven with large clinical trials. For bevacizumab only two clinical trials have been published and a head-to-head comparison is lacking to date. However, if proved non-inferior to ranibizumab, use of the off-label bevacizumab could reduce costs enormously without a loss in visual acuity. A cost-effectiveness study has been designed to substantiate this hypothesis. To compare the effectiveness and costs of 1.25 mg of bevacizumab to 0.5 mg ranibizumab given as monthly intravitreal injections during 6 months in patients with diabetic macular edema. It is hypothesized that bevacizumab is non-inferior to ranibizumab regarding its effectiveness. This is a randomized, controlled, double masked, clinical trial in 246 patients in seven academic trial centres in The Netherlands. The primary outcome measure is the change in best-corrected visual acuity (BCVA) in the study eye from baseline to month 6. Secondary outcomes are the proportions of patients with a gain or loss of 15 letters or more or a BCVA of 20/40 or more at 6 months, the change in leakage on fluorescein angiography and the change in foveal thickness by optical coherence tomography at 6 months, the number of adverse events in 6 months, and the costs per quality adjusted life-year of the two treatments.
- 7 July 2015
- Published by Springer Nature in BMC Ophthalmology
- Vol. 15 (1) , 71
Open AccessComparing the effectiveness and costs of Bevacizumab to Ranibizumab in patients with Diabetic Macular Edema: a randomized clinical trial (the BRDME study)
The effectiveness of ranibizumab in the treatment of diabetic macular edema has been proven with large clinical trials. For bevacizumab only two clinical trials have been published and a head-to-head comparison is lacking to date. However, if proved non-inferior to ranibizumab, use of the off-label bevacizumab could reduce costs enormously without a loss in visual acuity. A cost-effectiveness study has been designed to substantiate this hypothesis. To compare the effectiveness and costs of 1.25 mg of bevacizumab to 0.5 mg ranibizumab given as monthly intravitreal injections during 6 months in patients with diabetic macular edema. It is hypothesized that bevacizumab is non-inferior to ranibizumab regarding its effectiveness. This is a randomized, controlled, double masked, clinical trial in 246 patients in seven academic trial centres in The Netherlands. The primary outcome measure is the change in best-corrected visual acuity (BCVA) in the study eye from baseline to month 6. Secondary outcomes are the proportions of patients with a gain or loss of 15 letters or more or a BCVA of 20/40 or more at 6 months, the change in leakage on fluorescein angiography and the change in foveal thickness by optical coherence tomography at 6 months, the number of adverse events in 6 months, and the costs per quality adjusted life-year of the two treatments.
- 18 December 2009
- Published by Taylor & Francis in Current Eye Research
- Vol. 35 (1) , 31-36
Variable Clinical Spectrum of the Myocilin Gln368X Mutation in a Dutch Family with Primary Open Angle Glaucoma
Purpose: To describe the clinical phenotype in a family with primary open angle glaucoma harboring a p.Gln368X mutation in MYOC. Materials and Methods: We identified a proband with primary open angle glaucoma and the p.Gln368X MYOC mutation. She and her six siblings were examined clinically, including Heidelberg Retina Tomography II, and venous blood samples were screened for other variants in MYOC, WDR36, OPTN, and CYP1B1. Results: Four individuals showed the p.Gln368X MYOC mutation, no other genetic variations were assessed. Two of these four siblings had glaucomatous optic disc changes with corresponding visual field losses and abnormal Heidelberg Retina Tomography results by the Moorfields regression analysis, one had abnormal results by the Moorfields regression analysis but no visual field loss, and one showed no glaucomatous signs or symptoms at all. These findings did not correlate with the age of the affected individuals. Conclusion: In the primary open angle glaucoma family described here, we documented a wide range in clinical symptoms, demonstrating a highly variable penetrance of the MYOC p.Gln368X mutation.
- 18 December 2009
- Published by Taylor & Francis in Current Eye Research
- Vol. 35 (1) , 31-36
Variable Clinical Spectrum of the Myocilin Gln368X Mutation in a Dutch Family with Primary Open Angle Glaucoma
Purpose: To describe the clinical phenotype in a family with primary open angle glaucoma harboring a p.Gln368X mutation in MYOC. Materials and Methods: We identified a proband with primary open angle glaucoma and the p.Gln368X MYOC mutation. She and her six siblings were examined clinically, including Heidelberg Retina Tomography II, and venous blood samples were screened for other variants in MYOC, WDR36, OPTN, and CYP1B1. Results: Four individuals showed the p.Gln368X MYOC mutation, no other genetic variations were assessed. Two of these four siblings had glaucomatous optic disc changes with corresponding visual field losses and abnormal Heidelberg Retina Tomography results by the Moorfields regression analysis, one had abnormal results by the Moorfields regression analysis but no visual field loss, and one showed no glaucomatous signs or symptoms at all. These findings did not correlate with the age of the affected individuals. Conclusion: In the primary open angle glaucoma family described here, we documented a wide range in clinical symptoms, demonstrating a highly variable penetrance of the MYOC p.Gln368X mutation.
- 1 December 2007
- Vol. 122 (5) , 553
Novel human pathological mutations. Gene symbol: MYOC. Disease: primary open angle glaucoma.
- 1 December 2007
- Vol. 122 (5) , 553
Novel human pathological mutations. Gene symbol: MYOC. Disease: primary open angle glaucoma.
- 27 September 2007
- Vol. 13, 1793-801
Identification and functional characterization of a novel MYOC mutation in two primary open angle glaucoma families from The Netherlands.
Glaucoma is the second most prevalent cause of blindness worldwide, projected to affect more than 60 million people by 2010, 75% of which represents primary open angle glaucoma (POAG). Of the three genes, namely, Myocilin (MYOC), Optineurin (OPTN), and WD repeat-containing protein 36 (WDR36), which have been shown to cause POAG when defective, MYOC is the most frequently mutated gene, accounting for 3%-4% of all POAG cases. The purpose of this study was identification and functional characterization of MYOC mutations in adult-onset, high-pressure POAG patients from The Netherlands. The following criteria were required for study participants to be included: have at least two affected family members, an age of diagnosis of more than 35 years, intraocular pressure (IOP) of more than 22 mmHg, glaucomatous optic neuropathy in both eyes, visual field loss consistent with assessed optic neuropathy in at least one eye, and an open anterior chamber angle without morphological abnormalities by gonioscopy. Sequence analysis was performed in genomic DNA of 30 probands for the protein coding region of the MYOC gene. A Chinese hamster ovarian cell line (CHO-K1) was used to express wild type and mutant MYOC protein. Detergent solubility of MYOC was assayed and its secretory property was analyzed by immunoprecipitation. We recruited 250 individuals from 30 families (120 affected and 130 unaffected family members) with a positive history of POAG. We identified a novel mutation c.1288T>C (p.Phe430Leu) in exon 3 of MYOC in two unrelated families showing the same haplotype around the mutant allele. The novel mutation segregated completely with the disease in these families and was absent in 250 ethnically matched controls. All patients harboring this mutation showed severe glaucomatous damage, pointing to the deleterious effect of this mutation. Compared to the wild type, the mutant protein was less soluble when extracted with Triton X-100 and was secretion-defective. The novel MYOC mutation, p.Phe430Leu, has the same origin in both POAG families from The Netherlands. The pathogenic nature of this mutation is suggested by the severe phenotype of mutant patients and mistrafficking of mutant protein as observed for other severe disease-causing mutations of MYOC.
- 27 September 2007
- Vol. 13, 1793-801
Identification and functional characterization of a novel MYOC mutation in two primary open angle glaucoma families from The Netherlands.
Glaucoma is the second most prevalent cause of blindness worldwide, projected to affect more than 60 million people by 2010, 75% of which represents primary open angle glaucoma (POAG). Of the three genes, namely, Myocilin (MYOC), Optineurin (OPTN), and WD repeat-containing protein 36 (WDR36), which have been shown to cause POAG when defective, MYOC is the most frequently mutated gene, accounting for 3%-4% of all POAG cases. The purpose of this study was identification and functional characterization of MYOC mutations in adult-onset, high-pressure POAG patients from The Netherlands. The following criteria were required for study participants to be included: have at least two affected family members, an age of diagnosis of more than 35 years, intraocular pressure (IOP) of more than 22 mmHg, glaucomatous optic neuropathy in both eyes, visual field loss consistent with assessed optic neuropathy in at least one eye, and an open anterior chamber angle without morphological abnormalities by gonioscopy. Sequence analysis was performed in genomic DNA of 30 probands for the protein coding region of the MYOC gene. A Chinese hamster ovarian cell line (CHO-K1) was used to express wild type and mutant MYOC protein. Detergent solubility of MYOC was assayed and its secretory property was analyzed by immunoprecipitation. We recruited 250 individuals from 30 families (120 affected and 130 unaffected family members) with a positive history of POAG. We identified a novel mutation c.1288T>C (p.Phe430Leu) in exon 3 of MYOC in two unrelated families showing the same haplotype around the mutant allele. The novel mutation segregated completely with the disease in these families and was absent in 250 ethnically matched controls. All patients harboring this mutation showed severe glaucomatous damage, pointing to the deleterious effect of this mutation. Compared to the wild type, the mutant protein was less soluble when extracted with Triton X-100 and was secretion-defective. The novel MYOC mutation, p.Phe430Leu, has the same origin in both POAG families from The Netherlands. The pathogenic nature of this mutation is suggested by the severe phenotype of mutant patients and mistrafficking of mutant protein as observed for other severe disease-causing mutations of MYOC.
- 1 August 2007
- Published by American Medical Association (AMA) in Archives of Ophthalmology (1950)
- Vol. 125 (8) , 1100-1106
Clinical and Genetic Heterogeneity in Multifocal Vitelliform Dystrophy
Research from JAMA Ophthalmology — Clinical and Genetic Heterogeneity in Multifocal Vitelliform Dystrophy
- 1 August 2007
- Published by American Medical Association (AMA) in Archives of Ophthalmology (1950)
- Vol. 125 (8) , 1100-1106
Clinical and Genetic Heterogeneity in Multifocal Vitelliform Dystrophy
Research from JAMA Ophthalmology — Clinical and Genetic Heterogeneity in Multifocal Vitelliform Dystrophy
- 1 September 2005
- Published by American Medical Association (AMA) in Archives of Ophthalmology (1950)
- Vol. 123 (9) , 1237-1241
Genetic Risk of Rhegmatogenous Retinal Detachment
Research from JAMA Ophthalmology — Genetic Risk of Rhegmatogenous Retinal Detachment — A Familial Aggregation Study
- 1 September 2005
- Published by American Medical Association (AMA) in Archives of Ophthalmology (1950)
- Vol. 123 (9) , 1237-1241
Genetic Risk of Rhegmatogenous Retinal Detachment
Research from JAMA Ophthalmology — Genetic Risk of Rhegmatogenous Retinal Detachment — A Familial Aggregation Study
- 2 April 2004
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 242 (10) , 892-897
Autosomal dominant rhegmatogenous retinal detachment—clinical appearance and surgical outcome
Purpose To study the clinical appearance and surgical results of autosomal dominantly inherited rhegmatogenous retinal detachments (RRDs). Methods After prospective examination of all but two family members, the medical records of 16 affected patients (21 eyes) of two families from the Netherlands with autosomal dominantly inherited RRD were retrospectively evaluated. Special attention was paid to the age at onset, the ocular morphology and the clinical appearance of the RRD. The type and number of the various surgical procedures were analyzed with respect to preoperative appearance of the RRD, postoperative results and final visual acuity. Results The mean age at onset of RRD of affected individuals in families A and B was 37±18 years and 19±10 years, respectively. The mean ocular axial length in the two families was 24.7 mm and 26.7 mm. The mean number of retinal defects preoperatively found was 2.2 in family A and 7.1 in family B. Round, atrophic retinal holes predominated. Two of 21 affected eyes showed significant preoperative proliferative vitreoretinopathy. Pars plana vitrectomy was the primary procedure in 4 cases; extra ocular buckling was the initial procedure in 15 cases. One eye received scleral folding with diathermy as primary surgery. Redetachment following surgery occurred in 5 of 10 cases in family A and 4 of 10 eyes in family B. Anatomical success could be achieved in 9 of 10 and 8 of 10 eyes in families A and B, respectively. Conclusions In these families the prevalence of RRD is high. Most patients were affected at a relatively young age compared with non-genetically linked forms of RRD. Because of the low success rate of surgical intervention and, subsequently, the high number of operations necessary to achieve reattachment of the retina, the use of diagnostic genetic techniques to identify individuals at risk would be advisable. In these subjects measures to prevent RRD are an option, even when anatomical substrates of precursors of RRD are absent.
- 2 April 2004
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 242 (10) , 892-897
Autosomal dominant rhegmatogenous retinal detachment—clinical appearance and surgical outcome
Purpose To study the clinical appearance and surgical results of autosomal dominantly inherited rhegmatogenous retinal detachments (RRDs). Methods After prospective examination of all but two family members, the medical records of 16 affected patients (21 eyes) of two families from the Netherlands with autosomal dominantly inherited RRD were retrospectively evaluated. Special attention was paid to the age at onset, the ocular morphology and the clinical appearance of the RRD. The type and number of the various surgical procedures were analyzed with respect to preoperative appearance of the RRD, postoperative results and final visual acuity. Results The mean age at onset of RRD of affected individuals in families A and B was 37±18 years and 19±10 years, respectively. The mean ocular axial length in the two families was 24.7 mm and 26.7 mm. The mean number of retinal defects preoperatively found was 2.2 in family A and 7.1 in family B. Round, atrophic retinal holes predominated. Two of 21 affected eyes showed significant preoperative proliferative vitreoretinopathy. Pars plana vitrectomy was the primary procedure in 4 cases; extra ocular buckling was the initial procedure in 15 cases. One eye received scleral folding with diathermy as primary surgery. Redetachment following surgery occurred in 5 of 10 cases in family A and 4 of 10 eyes in family B. Anatomical success could be achieved in 9 of 10 and 8 of 10 eyes in families A and B, respectively. Conclusions In these families the prevalence of RRD is high. Most patients were affected at a relatively young age compared with non-genetically linked forms of RRD. Because of the low success rate of surgical intervention and, subsequently, the high number of operations necessary to achieve reattachment of the retina, the use of diagnostic genetic techniques to identify individuals at risk would be advisable. In these subjects measures to prevent RRD are an option, even when anatomical substrates of precursors of RRD are absent.
- Open Access
- 1 October 2003
- Published by American Medical Association (AMA) in Archives of Ophthalmology (1950)
- Vol. 121 (10) , 1452-1457
A Peculiar Autosomal Dominant Macular Dystrophy Caused by an Asparagine Deletion at Codon 169 in the Peripherin/RDS Gene
AUTOSOMAL DOMINANT hereditary macular dystrophies can be categorized into many types, often clinically subdivided by descriptive fundus signs and electrophysiologic findings. In general, age at onset, bilateral appearance, slow progression, gradual loss of visual acuity, and central visual field loss characterize these dystrophies.1 No entirely satisfactory categorization of the hereditary retinal dystrophies has yet been established. Identification of molecular causes shows a high degree of genetic and allelic heterogeneity.2 One of the best examples of allelic heterogeneity is the human retinal degeneration slow (peripherin/RDS) gene.3 To date, 70 different mutations in the peripherin/RDS gene have been associated with a spectrum of retinal phenotypes. They can be grouped into 4 broad categories: autosomal dominant retinitis pigmentosa (RP), digenic RP, progressive macular dystrophy, and pattern dystrophy.4 The mutations account for approximately 3% to 8% of all autosomal dominant RP cases, 5,6 7% to 10% of central retinal dystrophies, 7 and 18% of adult-onset vitelliform macular dystrophy (AVMD).8 Most mutations are restricted to single families and show a broad phenotypic spectrum in patients7; some mutations even cause intrafamilial variability in clinical expression.9 In this study, we describe the ocular features of several members of a family from the Netherlands, who invariably carry a novel 3–base pair (bp) deletion in the peripherin/RDS gene.
- 1 October 2003
- Published by American Medical Association (AMA) in Archives of Ophthalmology (1950)
- Vol. 121 (10) , 1452-1457
Open AccessA Peculiar Autosomal Dominant Macular Dystrophy Caused by an Asparagine Deletion at Codon 169 in the Peripherin/RDS Gene
AUTOSOMAL DOMINANT hereditary macular dystrophies can be categorized into many types, often clinically subdivided by descriptive fundus signs and electrophysiologic findings. In general, age at onset, bilateral appearance, slow progression, gradual loss of visual acuity, and central visual field loss characterize these dystrophies.1 No entirely satisfactory categorization of the hereditary retinal dystrophies has yet been established. Identification of molecular causes shows a high degree of genetic and allelic heterogeneity.2 One of the best examples of allelic heterogeneity is the human retinal degeneration slow (peripherin/RDS) gene.3 To date, 70 different mutations in the peripherin/RDS gene have been associated with a spectrum of retinal phenotypes. They can be grouped into 4 broad categories: autosomal dominant retinitis pigmentosa (RP), digenic RP, progressive macular dystrophy, and pattern dystrophy.4 The mutations account for approximately 3% to 8% of all autosomal dominant RP cases, 5,6 7% to 10% of central retinal dystrophies, 7 and 18% of adult-onset vitelliform macular dystrophy (AVMD).8 Most mutations are restricted to single families and show a broad phenotypic spectrum in patients7; some mutations even cause intrafamilial variability in clinical expression.9 In this study, we describe the ocular features of several members of a family from the Netherlands, who invariably carry a novel 3–base pair (bp) deletion in the peripherin/RDS gene.
- 1 September 2003
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 44 (9) , 4035-4043
Autosomal Dominant Rhegmatogenous Retinal Detachment Associated with an Arg453Ter Mutation in theCOL2A1Gene
Purpose. To investigate the clinical features and molecular causes of autosomal dominant rhegmatogenous retinal detachment (RRD) in two large families. methods. Clinical examination and linkage analysis of both families using markers flanking the COL2A1 gene associated with Stickler syndrome type 1, the loci for Wagner disease/erosive vitreoretinopathy (5q14.3), high myopia (18p11.31 and 12q21-q23), and nonsyndromic congenital retinal nonattachment (10q21). results. Fifteen individuals from family A and 12 individuals from family B showed RRD or retinal tears with minimal (family A) or no (family B) systemic characteristics of Stickler syndrome and no ocular features of Wagner disease or erosive vitreoretinopathy. The RRD cosegregated fully with a chromosomal region harboring the COL2A1 gene with maximum lod scores of 6.09 (family A) and 4.97 (family B). In family B, an Arg453Ter mutation was identified in exon 30 of the COL2A1 gene, that was previously described in a patient with classic Stickler syndrome. In family A, DNA sequence analysis revealed no mutation in the coding region and at the splice sites of the COL2A1 gene. conclusions. In two large families with RRD, linkage was found at the COL2A1 locus. In one of these families an Arg453Ter mutation was identified, which is surprising, because all predominantly ocular Stickler syndrome cases until now have been associated with protein-truncating mutations in exon 2, an exon subject to alternative splicing. In contrast, the Arg453Ter mutation and other protein-truncating mutations in the helical domain of COL2A1 have been associated until now with classic Stickler syndrome.
- 1 September 2003
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 44 (9) , 4035-4043
Autosomal Dominant Rhegmatogenous Retinal Detachment Associated with an Arg453Ter Mutation in theCOL2A1Gene
Purpose. To investigate the clinical features and molecular causes of autosomal dominant rhegmatogenous retinal detachment (RRD) in two large families. methods. Clinical examination and linkage analysis of both families using markers flanking the COL2A1 gene associated with Stickler syndrome type 1, the loci for Wagner disease/erosive vitreoretinopathy (5q14.3), high myopia (18p11.31 and 12q21-q23), and nonsyndromic congenital retinal nonattachment (10q21). results. Fifteen individuals from family A and 12 individuals from family B showed RRD or retinal tears with minimal (family A) or no (family B) systemic characteristics of Stickler syndrome and no ocular features of Wagner disease or erosive vitreoretinopathy. The RRD cosegregated fully with a chromosomal region harboring the COL2A1 gene with maximum lod scores of 6.09 (family A) and 4.97 (family B). In family B, an Arg453Ter mutation was identified in exon 30 of the COL2A1 gene, that was previously described in a patient with classic Stickler syndrome. In family A, DNA sequence analysis revealed no mutation in the coding region and at the splice sites of the COL2A1 gene. conclusions. In two large families with RRD, linkage was found at the COL2A1 locus. In one of these families an Arg453Ter mutation was identified, which is surprising, because all predominantly ocular Stickler syndrome cases until now have been associated with protein-truncating mutations in exon 2, an exon subject to alternative splicing. In contrast, the Arg453Ter mutation and other protein-truncating mutations in the helical domain of COL2A1 have been associated until now with classic Stickler syndrome.